HC Wainwright Comments on Bausch + Lomb Q1 Earnings

Bausch + Lomb Corporation (NYSE:BLCO) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Bausch + Lomb in a research report issued on Monday, February 23rd. HC Wainwright analyst Y. Chen anticipates that the company will earn $0.14 per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.74 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.27 EPS and FY2026 earnings at $0.78 EPS.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, February 18th. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03). Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The company had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.38 billion. During the same period in the prior year, the firm earned $0.25 earnings per share. Bausch + Lomb’s revenue was up 9.8% on a year-over-year basis.

Several other equities analysts have also recently issued reports on BLCO. Citigroup upped their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $19.00 target price on shares of Bausch + Lomb in a research report on Friday, January 9th. Stifel Nicolaus set a $16.00 price target on Bausch + Lomb in a research report on Thursday. Evercore set a $18.00 price objective on Bausch + Lomb and gave the stock an “in-line” rating in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $18.25.

Bausch + Lomb Price Performance

Shares of NYSE:BLCO opened at $17.94 on Tuesday. Bausch + Lomb has a 52-week low of $10.45 and a 52-week high of $18.12. The company has a market capitalization of $6.36 billion, a PE ratio of -17.59, a price-to-earnings-growth ratio of 0.73 and a beta of 0.61. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.04 and a current ratio of 1.55. The company has a fifty day moving average of $17.08 and a 200-day moving average of $15.90.

Hedge Funds Weigh In On Bausch + Lomb

Several large investors have recently bought and sold shares of the stock. Cetera Investment Advisers lifted its holdings in Bausch + Lomb by 3.9% during the fourth quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock worth $320,000 after acquiring an additional 711 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Bausch + Lomb by 38.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,757 shares of the company’s stock worth $64,000 after buying an additional 1,039 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Bausch + Lomb by 104.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after buying an additional 1,136 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after acquiring an additional 1,403 shares during the period. Finally, Woodline Partners LP lifted its position in shares of Bausch + Lomb by 0.5% during the first quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock worth $4,536,000 after acquiring an additional 1,436 shares in the last quarter. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.